Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mechanobiology and Cardiovascular Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PIEZO1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PIEZO1 Extracellular Domain (Cap Region) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View PIEZO1 Products |
| Gene Delivery | PIEZO1 Lentivirus Premade Particles Full-length ORF for stable cell line construction (Calcium Flux/Patch Clamp assays). |
View PIEZO1 Products |
| Benchmark Ab | Anti-PIEZO1 Recombinant Antibody Sequence-verified positive control for flow cytometry and functional blocking. |
View PIEZO1 Products |
| Validator | PIEZO1 siRNA Set For knockdown verification in primary endothelial or tumor cells. |
View PIEZO1 Products |
| Related Target A | PIEZO2 Homologous mechanosensitive channel. Crucial for selectivity and counter-screening to avoid off-target somatosensory toxicity. |
View PIEZO2 Products |
| Related Target B | TRPV4 Mechanosensitive calcium-permeable channel. Synergistic target in vascular shear stress and fibrotic disease pathways. |
View TRPV4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Multi-pass Membrane Target | Lentivirus-mediated stable overexpressing cell lines preserve native 38-transmembrane homotrimeric structure. |
| PIEZO1 vs. PIEZO2 Selectivity Screening | High-purity PIEZO2 and PIEZO1 target reagents available for simultaneous dual-channel specificity assays. |
| Lack of Controls | Clinical-grade benchmark antibodies and chemical control validation protocols included |
| False Positives | Validated siRNA sets included for target-specific knockdown rescue experiments |
Live PIEZO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PIEZO1, a pioneering mechanosensitive ion channel, represents a major frontier in mechanopharmacology. The global pipeline is expanding from academic target validation into industrial drug discovery, focusing on cardiovascular diseases, pulmonary arterial hypertension (PAH), liver/kidney fibrosis, and oncology. As first-generation chemical modulators like Yoda1 (agonist) and GsMTx4 (antagonist) serve as chemical probes, the next wave of R&D is targeting highly selective small molecules and monoclonal antibodies designed to modulate mechanical gating without systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Novartis, Mechanotherapeutic Startups | Pulmonary Hypertension, Fibrosis | High-throughput Calcium Flux Screening (Need Lentivirus for Stable Cell Lines) |
| Monoclonal Antibodies | Biopharma Innovators | Vascular Diseases, Solid Tumors | Conformational Binding & Blocking Assays (Need HEK293 Expressed Cap Domain Protein) |
| Small Molecule Activators | Academic Spin-offs | Anemia, Lymphatic Disorders | Selectivity profiling against PIEZO2 (Need PIEZO2 control reagents) |